Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study

20‐year follow‐up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)

(2020) Heidi Taipale et al.   World Psychiatry

Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia

(2020) John M. Kane et al.   JAMA Psychiatry

Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms

(2019) Yutaro Shimomura et al.   SCHIZOPHRENIA RESEARCH

20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia

(2018) Jari Tiihonen et al.   AMERICAN JOURNAL OF PSYCHIATRY

Clinical risk factors for the development of tardive dyskinesia

(2018) Marco Solmi et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia

(2018) Hiroyoshi Takeuchi et al.   NEUROPSYCHOPHARMACOLOGY

Factors Associated With Successful Medication Discontinuation After a Randomized Clinical Trial of Relapse Prevention in First-Episode Psychosis

(2018) Christy L. M. Hui et al.   JAMA Psychiatry

A 20-Year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia

(2017) Martin Harrow et al.   PSYCHIATRY RESEARCH

Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis

(2017) J. Vermeulen et al.   PSYCHOLOGICAL MEDICINE

Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia

(2017) Jari Tiihonen et al.   JAMA Psychiatry

Comparison of long-acting and oral antipsychotic treatment effects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: An exploratory analysis of the PRIDE study

(2017) H. Lynn Starr et al.   SCHIZOPHRENIA RESEARCH

Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?

(2016) Robin M. Murray et al.   BRITISH JOURNAL OF PSYCHIATRY

From prescription drug purchases to drug use periods – a second generation method (PRE2DUP)

(2015) Antti Tanskanen et al.   BMC Medical Informatics and Decision Making

Real-World Outcomes of Paliperidone Palmitate Compared to Daily Oral Antipsychotic Therapy in Schizophrenia

(2015) Larry Alphs et al.   JOURNAL OF CLINICAL PSYCHIATRY

Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy

(2013) Lex Wunderink et al.   JAMA Psychiatry

Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis

(2012) Stefan Leucht et al.   LANCET

A Systematic Review and Meta-Analysis of Recovery in Schizophrenia

(2012) E. Jaaskelainen et al.   SCHIZOPHRENIA BULLETIN

Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia

(2012) George Bartzokis et al.   SCHIZOPHRENIA RESEARCH

Risk factors for relapse following treatment for first episode psychosis: A systematic review and meta-analysis of longitudinal studies

(2012) M. Alvarez-Jimenez et al.   SCHIZOPHRENIA RESEARCH

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

(2011) Marc De Hert et al.   Nature Reviews Endocrinology

Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia

(2011) Julie Kreyenbuhl et al.   SCHIZOPHRENIA RESEARCH

Cannabis Use and the Course of Schizophrenia: 10-Year Follow-Up After First Hospitalization

(2010) Daniel J. Foti et al.   AMERICAN JOURNAL OF PSYCHIATRY